Literature DB >> 16436130

Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes.

H Komatsu1, G Lauer, O G Pybus, K Ouchi, D Wong, S Ward, B Walker, P Klenerman.   

Abstract

Hepatitis C virus (HCV) is a variable RNA virus that can readily establish persistent infection. Cellular immune responses are important in the early control of the virus. Evidence from animal models suggests that mutation in epitopes recognized by CD8+ T lymphocytes may play an important role in the establishment of persistence but in human persistent infection, equivalent evidence is lacking. We investigated this by analysing a unique resource: viruses from a set of chronically HCV-infected individuals in whom the CD8+ T-cell responses in liver had previously been accurately mapped. Virus was sequenced in seven individuals at 10 epitopes restricted by 10 human leucocyte antigen (HLA) molecules. Two main patterns emerged: in the majority of epitopes sequenced, no variation was seen. In three epitopes, mutations were identified which were compatible with immune escape as assessed using phylogenetic and/or functional studies. These data suggest that - even where specific intrahepatic T cells are detectable - many epitopes do not undergo mutation in chronic human infection. On the contrary, virus may escape from intrahepatic CD8+ T-cell responses in a 'patchy' manner in certain specific epitopes. Furthermore, longitudinal studies to identify the differences between 'selecting' and 'nonselecting' intrahepatic CD8+ T-cell responses are needed in HCV infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436130     DOI: 10.1111/j.1365-2893.2005.00676.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

Review 2.  Innate and Adaptive Immune Responses in Chronic HCV Infection.

Authors:  Lynn B Dustin
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

Review 3.  Immune control and failure in HCV infection--tipping the balance.

Authors:  Lynn B Dustin; Siobhán B Cashman; Stephen M Laidlaw
Journal:  J Leukoc Biol       Date:  2014-07-11       Impact factor: 4.962

Review 4.  T-cell responses in hepatitis B and C virus infection: similarities and differences.

Authors:  Julia Schmidt; Hubert E Blum; Robert Thimme
Journal:  Emerg Microbes Infect       Date:  2013-03-27       Impact factor: 7.163

5.  Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection.

Authors:  Karen Fitzmaurice; Danijela Petrovic; Narayan Ramamurthy; Ruth Simmons; Shazma Merani; Silvana Gaudieri; Stuart Sims; Eugene Dempsey; Elizabeth Freitas; Susan Lea; Susan McKiernan; Suzanne Norris; Aideen Long; Dermot Kelleher; Paul Klenerman
Journal:  Gut       Date:  2011-05-06       Impact factor: 23.059

6.  Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection.

Authors:  Vicki M Fleming; Gillian Harcourt; Eleanor Barnes; Paul Klenerman
Journal:  J Gen Virol       Date:  2010-01-27       Impact factor: 3.891

7.  Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses.

Authors:  Magdalena Molero-Abraham; Esther M Lafuente; Darren R Flower; Pedro A Reche
Journal:  Clin Dev Immunol       Date:  2013-11-21

Review 8.  Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C.

Authors:  Julia Peña-Asensio; Henar Calvo; Miguel Torralba; Joaquín Miquel; Eduardo Sanz-de-Villalobos; Juan-Ramón Larrubia
Journal:  Cells       Date:  2021-03-03       Impact factor: 6.600

9.  Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response.

Authors:  Eva Dazert; Christoph Neumann-Haefelin; Stéphane Bressanelli; Karen Fitzmaurice; Julia Kort; Jörg Timm; Susan McKiernan; Dermot Kelleher; Norbert Gruener; John E Tavis; Hugo R Rosen; Jaqueline Shaw; Paul Bowness; Hubert E Blum; Paul Klenerman; Ralf Bartenschlager; Robert Thimme
Journal:  J Clin Invest       Date:  2009-01-12       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.